TipRanks
Healthy Extracts (HYEX)
OTHER OTC:HYEX
US Market
Want to see HYEX full AI Analyst Report?

Healthy Extracts (HYEX) AI Stock Analysis

8 Followers

Top Page

HYEX

Healthy Extracts

(OTC:HYEX)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - Gpt-5.6Sol)
Rating:47Neutral
Price Target:
$0.99
▼(-15.81% Downside)
Action:Reiterated
Date:09/18/26
The score is held back primarily by continued operating and net losses alongside increased debt and limited cash-flow coverage, despite improving revenue and recently positive free cash flow. Technicals are also weak, with the stock trading below all key moving averages and negative MACD. Additional downside risk comes from multiple recent executive/board resignations with positions left vacant.
Positive Factors
Revenue Growth and Gross Margin
Revenue growth alongside a strong gross margin indicates improving scale and attractive unit economics in the nutraceutical business. If sustained, this combination can support greater operating leverage, fund product and distribution investment, and strengthen the company’s ability to convert sales expansion into future profitability.
Negative Factors
Persistent Operating and Net Losses
The company has not yet translated revenue growth and roughly 61% gross margins into sustainable operating profitability. Continued EBIT and net losses can consume financial resources, limit internally funded investment, and leave results vulnerable if growth slows before sufficient operating leverage is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth and Gross Margin
Revenue growth alongside a strong gross margin indicates improving scale and attractive unit economics in the nutraceutical business. If sustained, this combination can support greater operating leverage, fund product and distribution investment, and strengthen the company’s ability to convert sales expansion into future profitability.
Read all positive factors

Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)

Healthy Extracts Business Overview & Revenue Model

Company Description
Healthy Extracts Inc., through its various divisions, specializes in the global and domestic research, development, and sale of natural botanical products. Its portfolio encompasses dietary supplements crafted for cardiovascular wellness, alongsid...

Healthy Extracts Financial Statement Overview

Summary
Financials show an improving trajectory: TTM revenue grew to $6.29M (~21%) with strong gross margin (~61%), and both operating cash flow and free cash flow turned positive (~$0.50M). However, profitability remains negative (EBIT margin ~-15%, net margin ~-14%) and debt has increased versus the prior year, leaving limited cash-flow coverage.
Income Statement
44
Neutral
Balance Sheet
58
Neutral
Cash Flow
55
Neutral
BreakdownTTMDec 2025Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue6.29M4.51M3.11M2.49M2.25M1.47M
Gross Profit3.85M2.42M1.91M1.62M1.37M695.08K
EBITDA-486.38K-791.66K-183.15K-2.24M-910.71K-1.88M
Net Income-879.36K-881.12K-840.67K-2.47M-983.12K-1.99M
Balance Sheet
Total Assets32.61M27.82M2.38M2.64M2.78M3.03M
Cash, Cash Equivalents and Short-Term Investments189.96K146.94K112.02K19.44K65.65K222.10K
Total Debt9.07M2.64M941.90K1.13M593.52K342.62K
Total Liabilities10.17M3.80M1.97M1.68M902.79K558.84K
Stockholders Equity22.44M24.03M410.38K954.59K1.88M2.47M
Cash Flow
Free Cash Flow500.27K146.22K281.97K-415.75K-342.95K-997.30K
Operating Cash Flow500.27K165.52K281.97K-415.75K-334.96K-901.30K
Investing Cash Flow171.57K56.30K0.000.00-5.34K-96.00K
Financing Cash Flow-682.38K-186.91K-189.39K369.54K239.52K1.16M

Healthy Extracts Technical Analysis

Technical Analysis Sentiment
Negative
Last Price1.17
Price Trends
50DMA
1.11
Negative
100DMA
1.47
Negative
200DMA
1.67
Negative
Market Momentum
MACD
-0.03
Positive
RSI
36.46
Neutral
STOCH
>-0.01
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Negative. The current price of 1.17 is above the 20-day moving average (MA) of 1.04, above the 50-day MA of 1.11, and below the 200-day MA of 1.67, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 36.46 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HYEX.

Healthy Extracts Risk Analysis

Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price. Q4, 2023
2.
We have broad discretion in the use of our cash, and may not use it effectively. Q4, 2023

Healthy Extracts Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
57
Neutral
$28.21M-5.04-14.03%―-21.12%-109.07%
54
Neutral
$20.98M-1.41-52.89%―-13.27%27.11%
52
Neutral
$37.91M-2.07-21.10%―489.78%45.39%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
47
Neutral
$19.02M-8.12-3.72%―84.13%38.29%
46
Neutral
$65.18M-6.09-47.10%31.86%-25.68%-244.92%
41
Neutral
$23.39M-0.35-118.89%―33.82%34.05%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYEX
Healthy Extracts
1.29
-0.94
-42.15%
RMTI
Rockwell Med
7.00
-4.40
-38.60%
SCYX
SCYNEXIS
3.81
-2.21
-36.75%
AYTU
Aytu BioScience
1.93
-0.28
-12.67%
CPIX
Cumberland Pharmaceuticals
4.35
1.88
75.90%
COSM
Cosmos Holdings
0.23
-0.68
-74.64%

Healthy Extracts Corporate Events

Executive/Board Changes
Healthy Extracts Announces Board Change After Director Resignation
Negative
Sep 18, 2026
Healthy Extracts, operating in the broader health and wellness sector, is overseen by a board of directors responsible for guiding its corporate governance and strategic direction. The company relies on its board committees to manage oversight fun...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 18, 2026